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Identification of a Selectivity Determinant for
Inhibition of Tumor Necrosis Factor- Converting
Enzyme by Comparative Modeling
Black and colleagues at Immunex [7] and Moss and
colleagues at Glaxo [8] reported the identification of a
new metalloproteinase termed TACE (TNF-alpha con-
verting enzyme) that effectively cleaves the 26 kDa pro-
TNF- to the soluble 17 kDa protein.
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TACE, a member of the ADAM (a disintegrin and met-2 Discovery Chemistry
alloproteinase) family of enzymes, has sequence similar-Bristol-Myers Squibb Company
ity to the reprolysin or snake venom family of metallopro-Experimental Station
teinases [7]. The importance of this enzyme as aWilmington, Delaware 19880
therapeutic target was supported by the positive data,
generated in in vitro and in vivo models of inflammatory
disease, using previously identified matrix metallopro-Summary
teinase (MMP) inhibitors that also inhibit TACE. While
these inhibitors are important tools for biological discov-Inhibition of tumor necrosis factor- converting en-
ery, they are not suitable for drug development. A majorzyme (TACE) is a widespread objective in the search
flaw in their profile may be the broad spectrum of activityfor disease modifying agents to combat rheumatoid
against related metalloproteinases, primarily membersarthritis and other autoimmune diseases. Until re-
of the matrix metalloproteinases. The MMPs are a largecently, most of the inhibitors in the literature have
family of enzymes (20 currently known) involved inshown concomitant activity against the related matrix
both normal and pathological processes primarily asso-metalloproteinases (MMPs), producing undesired side
ciated with degradation and remodeling of macromole-effects. Here we describe the successful search for
cules contained in the extracellular matrix. While it isa TACE selectivity mechanism. We built a homology
possible that the broad spectrum (TACE plus MMP) in-model based on the crystal structure of the related
hibitory activity of the initial TACE leads may contributesnake venom protein atrolysin. Comparison of the
to the overall efficacy of these molecules, their nonselec-model with crystal structures of MMPs suggested a
tive profile greatly increases the possibility of inducinguniquely shaped S1 pocket that might be exploited
undesirable side effects on prolonged dosing in animals
for selectivity. A novel -lactam scaffold [1] was used
or humans. For example, broad-spectrum MMP inhibi-
to explore the activity profile of P1 sidechains, re- tors such as marimastat [9], prinomastat [10], and
sulting in highly selective compounds consistent with CGS27023A [11] have been associated with the side
this hypothesis. Transferability of the hypothesis was effect of musculoskeletal pain in human clinical trials.
then demonstrated with five other distinct scaffolds. Comparison of the protein sequence of TACE with
MMPs reveals low overall homology but high sequence
Introduction similarity in the active site regions of the enzymes. It is
likely the reason that identification of selective inhibitors
Tumor necrosis factor- (TNF-), a proinflammatory cy- of TACE proved elusive until recently [12, 1, and refer-
tokine, is a key mediator of inflammatory disorders such ences therein]. It was our intention to identify selective
as rheumatoid arthritis (RA) and Crohn’s disease. In inhibitors of TACE that could be used to evaluate the
1994, studies by Centocor and the Kennedy Institute dependence of TNF- processing on this single enzyme
demonstrated the striking effect of an anti-TNF- anti- and, more importantly, to evaluate the efficacy and ther-
body (cA2) in treating rheumatoid arthritis patients [2]. apeutic potential of such inhibitors in vivo. This report
This humanized antibody now known as infliximab and details our use of computer-assisted drug design, based
the TNFR II receptor fusion protein etanercept have on sequence information of TACE and publicly available
gained approval as therapeutics for the treatment of RA X-ray crystallographic structures of MMPs and snake
and Crohn’s disease [3, 4]. The validation of TNF- as venom proteins, in the development of selective inhibi-
a therapeutic target by these systemically injectable tors of TACE. Of significance, we demonstrate how se-
macromolecules has led to a number of small-molecule quence information across a family of closely related
approaches to inhibition of this cytokine [5]. enzymes can be combined with comparative modeling
Gearing and coworkers at British Biotech discovered of the target enzyme to identify the regions to exploit in
that the precursor of TNF- (pro-TNF-) was processed attaining selectivity. The derivation of a TACE homology
to the soluble form through the action of a metalloprotei- model, pinpointing of key active site regions, and selec-
nase [6]. In addition, TNF- release from cells could be tion of appropriate chemical substituents to maximize
TACE inhibition while sparing the activity of closely re-inhibited by small-molecule metalloproteinase inhibi-
lated enzymes are described.tors. These findings suggested an attractive small-mole-
cule enzymatic target for drug design. Subsequently
Results and Discussion
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Reprolysins and MMPs belong to the metzincin family3 Present address: Incyte Genomics, Inc., 1090 Elkton Road, Newark,
Delaware 19711. of zinc endoproteinases whose catalytic site contains
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a zinc ion coordinated by three histidines. Just below identical three-dimensional structures. Thus we felt
there was little to be gained in basing a model on morethis active site is located a conserved methionine resi-
due which gives name to the family. The metzincins are than one homolog and made the arbitrary choice of
atrolysin as a model for TACE. The initial alignment of thezymogens, having an N-terminal propeptide which must
be cleaved in order to activate their catalytic domains. two sequences was taken from a multiple one of TACE
and a set of reprolysins. An iterative process of modelAll except MMP-7 contain a hemopexin-like domain
C-terminal to the catalytic portion. In addition, the gela- generation, model inspection, and alignment modifica-
tion followed (see Experimental Procedures). Since 25%tinases MMP-2 and MMP-9 have a fibronectin-like inser-
tion within the catalytic domain [13]. of the identical residues fall within the catalytic site re-
gion, and because of the large number of inserted resi-The sequences of MMP-1, -2, -3, -8, and -9 were
aligned, as were a representative set of reprolysins (see dues in TACE, there were numerous ways in which the
sequences could be aligned while still maintaining aboutExperimental Procedures). The catalytic domains of the
MMPs are very similar, with approximately 55%–65% 29% sequence identity. As the process of model genera-
tion progressed, stretches of sequence similarity be-sequence identity, so despite short insertions, the se-
quences could be aligned unambiguously. The set of came concentrated into segments for which atrolysin
displayed well-defined secondary structure. Our finalreprolysins is at least as similar. For example, 80% of
the residues of the catalytic domains of adamalysin and alignment is shown in Figure 1. A sequence alignment
of adamalysin with TACE, in which several of the atrolysin are identical.
TACE contains the zinc binding motif HExxHxxGxxH strands are aligned differently, was subsequently pub-
lished by Gomis-Ruth et al. [19].characteristic of metzincins, as well as their conserved
triplet MxP. Apart from these two segments, we could The C-terminal domain was easier to align than the
larger N-terminal one. Early on in the model-buildingdetect essentially no sequence similarity between TACE
and MMPs. We did find almost 30% identity between process, we identified a disulfide bridge between
Cys204 and Cys234 (numbering from Pro1 to Ser255;TACE and the reprolysin family, but alignment was com-
plicated by the fact that the sequences of the catalytic see Figure 1). Concentrating our model optimization ef-
forts on the characteristic  sheet and three helices,domains were of unequal length (TACE having an addi-
tional 56 residues), and even approximate locations of and on loops abutting the prime side of the active site
groove, we made little attempt to optimize the otherthe necessary insertions could not in all cases be deter-
mined based on sequence alone. faces of the globular structure. We reasoned that with
so many inserted residues, a model which is accurate
everywhere is unlikely to be achieved and that we should
Building the Homology Model therefore concentrate on the core of the protein and
Many of the known MMP inhibitors are also highly effec- loops at the active site. In our final alignment, three of
tive against TACE. It was therefore conjectured that the the six cystine residues occur in, or on the edge of,
enzyme active sites must have structural similarity. This inserted segments. Because of this, we did not predict
belief was reinforced by the sequence analysis, because which of the four unpaired cystine residues would link
in crystal structures the active site sequence motifs of with each other, although we were convinced all six
reprolysins and MMPs are superimposable. Our intent would form disulfide bonds.
was to create a model of TACE that would drive the
identification of inhibitors highly selective for the en-
zyme. The medicinal chemistry effort in our laboratory Analysis of the Homology Model
The atomic structures and molecular surfaces of thewas, at that time, targeted on P3 and P4 (notation of
Schechter and Berger [14]) as determinants of selectiv- TACE model and MMP crystal structures were inspected
to identify opportunities for incorporating selectivity intoity, so we particularly wanted to focus on the composi-
tion and conformation of the protein segments forming inhibitors. Although we had hoped to locate opportuni-
ties for selective inhibition at S3 and S4, comparisonS3 and S4 of TACE.
Both the MMP and reprolysin families exhibit a char- of the TACE model with MMP structures indicated the
most striking difference to be their S1 pockets. Inacteristic topology consisting of a five-stranded  sheet
and three  helices [15]. The enzymes are organized MMP-3, S1 extends straight back from the protein sur-
face, whereas that of the TACE model exhibits a dis-into two domains, an upper consisting of the  sheet
and two  helices and a lower containing the third helix tinctly curved shape. S1 of MMP-1 is foreshortened by
an arginine side chain and MMP-8’s by another arginineas well as the MxP triplet and the following 8–10 resi-
dues, which form the outer side of S1 and are known 6 or 7 A˚ deeper into the pocket, but both are otherwise
similar to that of MMP-3.as the P1 loop. MMPs bind a second, structural zinc
in addition to the catalytic one and a number of structural To probe the suggested difference in pocket size and
shape, we utilized the crystal structure of MMP-3 inhib-calcium ions while reprolysins have no additional zinc
or other metal binding sites [16]. Whereas the catalytic ited by a molecule having a biphenyl moiety at P1 [20].
This complex was chosen because the inhibitor’s P1domains of the MMPs have no disulfides, both atrolysin
and adamalysin (the reprolysins whose structures have substituent was the longest of those in MMP/inhibitor
crystal structures known to us at that time. Althoughbeen determined [17, 18]) contain two disulfide bridges
[16], and TACE has six cystine residues. the zinc-chelating unit is a carboxylic acid rather than
the more common hydroxamic acid, it had been shownIn accord with their very similar sequences, atrolysin
(1htd.pdb) and adamalysin (1iag.pdb) have essentially that the two can bind in an identical fashion [21].
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Figure 1. Sequence Alignment of Atrolysin
and TACE Used in Building the Homology
Model
Identical amino acid residues are highlighted
in yellow, similar pairs in green. Secondary
structural assignments for Atrolysin were
taken from Protein Data Bank entry 1htd and
are indicated above the sequence. Segments
of TACE that were modeled correctly, in the
sense that the model and crystal structure
superimpose, are indicated by blue lines.
Thus, assuming that inhibitors would bind similarly in nine, a very small residue that may open the side of the
pocket to solvent (Figure 4).MMPs and TACE, we overlaid the model of TACE with
the crystal structure of MMP-3 by superimposing These observations strongly suggested (1) that selec-
tivity could be achieved by suitable modification of P1C-alphas of residues of the catalytic site HExxHxxGxxH
motif and examining the molecular surfaces of the pock- and (2) that the designated substituent should have, or
should be able to adopt, a bent conformation.ets and their orientation with respect to the inhibitor
(Figure 2). In the crystal structure of inhibited MMP-3,
S1 is a linear tunnel with the biphenyl centered within Discovery of TACE-Selective P1 Groups
The search for selective TACE inhibitors started with a(Figure 2A); the inhibitor binds to MMP-3 with Ki  21
nM. In the superimposed TACE model, S1 has a dis- novel -lactam hydroxamate scaffold, designed from
the structure of MMP-3 and MMP inhibitors reported intinctly bent shape (Figure 2B), and the distal ring collides
with the pocket wall; when tested in TACE, the inhibitor the literature [1, and references therein]. One of the early
analogs, biphenyl lactam 1a, was only weakly active inwas inactive.
Rationale for the difference in shape is suggested by pTACE and MMP-1 (Table 1), but potent for MMP-2 and
-9 (with Ki’s of 82 and 35 nM, respectively). Based oncomparison of the sequences (Figure 3). In MMPs, the
second residue following the MxP triplet is tyrosine, computer analysis described above (see Analysis of the
Homology Model), we conjectured that the rigid 4-biphe-conserved in all known members of the family. As early
as 1994, an NMR study of inhibited MMP-3 by Gooley nyl group of 1a would occupy the deep and linear S1
pocket of MMP-2 and -9 while being too long to fit intoand colleagues [22] had identified this tyrosine as con-
tacting P1 and forming one side of S1. For reprolysins, the shallow S1 of MMP-1. The lack of TACE potency
had been anticipated because it was in accord with ourthe equivalent position is occupied by a smaller residue
such as isoleucine or leucine. In TACE, there is an ala- conformational hypothesis of a curved S1.
Figure 2. Slice through the Center of (A) the Crystal Structure of the MMP-3/Inhibitor Complex and (B) Inhibitor with the Homology Model of
TACE
(B) was made by overlaying the catalytic site residues of the TACE model with those of the MMP-3 crystal structure. In (B), MMP-3 is not
shown. The structure of the inhibitor is given in approximately the same orientation as in the models.
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the Amer. Chem. Soc., abstract]. It was reported to be
a subnanomolar inhibitor of MMP-2 and -9 (Table 1).
Replacing the chlorophenoxy group of RS-113,456 with
a (2,6-dimethyl-4-pyridinyl)methoxy P1 decreased the
affinity for MMP-2 and -9 by greater than 4000-fold (2b).
Unfortunately, 2b is only moderately active in pTACE,
considerably less potent than the lactam analog 1e (131
versus 14 nM). However, pTACE potency was greatly
improved using a 4-quinolinylmethoxy group (2c), yield-
ing a 4 nM inhibitor with excellent selectivity.
Prinomastat (3a) is another potent MMP inhibitor that
Figure 3. Alignment of Sequences of MMP and Reprolysin Family advanced to development [23]. Incorporation of aMembers with TACE
4-quinolinylmethoxy group to the thiomorpholine core
Shown are the residues of the active site from just before the charac-
of prinomastat provided a potent TACE inhibitor, 3b.teristic HExxHxxGxxH motif through the MxP triad to the beginning
In contrast to the RS-113,456 series, 3b is surprisinglyof the S1 loop.
active for the three MMPs, with Ki’s all under 100 nM. The
(2,6-dimethyl-4-pyridinyl)methoxy analog 3c attenuated
To improve TACE potency and ultimately address se- the potency for MMPs (Ki 250 nM) while modestly
lectivity over MMPs, lactams with a more flexible P1 improving pTACE potency. Affinity for pTACE and selec-
were synthesized. The 4-phenoxyphenyl analog 1b in- tivity were further enhanced using a (3,5-dimethoxyphe-
creased pTACE potency to 185 nM. An even more flexi- nyl)methoxy P1 group (3d). In both the RS-113,456 and
ble 4-benzyloxyphenyl P1 group (1c) resulted in a 4 nM prinomastat series, we demonstrated that by modifying
inhibitor of pTACE, greater than 3000-fold enhancement the P1 group alone, one can convert a potent MMP
relative to 1a. This suggested that the flexible benzyloxy- inhibitor to ones that are potent for pTACE and selective
phenyl P1 can adopt the conformation necessary for over all three MMPs tested.
good binding to TACE. 1c remained potent for MMP-2 In an attempt to design inhibitors structurally distinct
and -9, most likely because the benzyloxyphenyl group from the prinomastat series, the sulfonyl group was first
can also adopt a more linear conformation. replaced by acetyl to give acetamide 4a. We were de-
Further elaboration of the benzyl ether led to the dis- lighted to find that 4a remains potent for pTACE. Replac-
covery of 3,5-dimethylbenzyl as a TACE-selective P1 ing the thiomorpholine ring of 4a by piperidine (4b)
group (1d) with 1000-, 1400-, and 400-fold selectivity yielded a pTACE inhibitor with good potency, albeit
for pTACE over MMP-1, -2, and -9, respectively. This 7-fold less than 4a. The pyrrolidine analog 4c is even
exquisite selectivity appears to be largely due to steric less potent. But in all cases, good selectivity over MMPs
effects, because replacement of the benzyl group with was maintained, again demonstrating effectiveness of
pyridinylmethyl (1e), quinolinylmethyl (1f), or a benzyl the new P1 groups.
group having different substituents [1] had little effect The novel MMP-2 inhibitor 5a incorporates a rationally
on the selectivity profile. Substitution at both 3 and 5 designed benzothiadiazepine scaffold [24]. To improve
positions of the benzyl ether is, however, required for its potency, the benzyloxy analog 5b was synthesized.
good selectivity; monomethyl substitution (1g) is much Surprisingly, it is less potent in the pTACE assay than
less selective. 5a (705 nM versus 274 nM), indicating a binding mode
The TACE-selective P1 groups were next incorpo- that differs somewhat from that of the previously de-
rated into two series of potent MMP inhibitors reported scribed lactam series. The potency improved incremen-
in the literature. RS-113,456 (2a) was derived from a tally with dimethylbenzyloxy (5c) and substantially with
-sulfonylhydroxamic acid and advanced to human clin- a dimethoxybenzyloxy group (5d). We hypothesize that
the bulky benzothiadiazepine scaffold induces a slightical trials [J.A. Campbell et al., 1998, 216th Meeting of
Figure 4. TACE Homology Model (Green) Su-
perimposed on the Active Site of Inhibited
MMP-3 (PDB File 1sln; Light Red)
The catalytic zinc ion (orange) is coordinated
by three histidine residues. Also shown is ty-
rosine 223 (light red) of MMP-3, which occu-
pies the outer edge of the S1 pocket, and
the alanine (green), which replaces it in TACE.
Inhibitor L-702,842 (from 1sln.pdb) is de-
picted in purple. Other side chains, portions
of the backbone of both proteins, and parts
of the inhibitor are omitted for clarity. The
figures were made with program MOLSCRIPT
[35]. The chemical composition of the inhibi-
tor, in approximately the same orientation as
in the Figure, is shown to the right.
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Table 1. In Vitro Profile of TACE Inhibitors
R pTACE (IC50, nM)a MMP-1 (Ki, nM) MMP-2 (Ki, nM) MMP-9 (Ki, nM)
1a Phenyl 13000 2288 82 35
1b Phenoxy 185 143 3 2
1c benzyloxy 4 5000 19 29
1d (3,5-dimethylphenyl)methoxy 4 4747 5812 1634
1e (2,6-dimethyl-4-pyridinyl)methoxy 14 5000 1585 688
1f (2-methyl-4-quinolinyl)methoxy 1 5000 2050 3000
1g (3-methylphenyl)methoxy 6 5000 18 6
2ab 4-chlorophenoxy – 590 0.22 0.58
2b (2,6-dimethyl-4-pyridinyl)methoxy 131 5000 1744 2128
2c 4-quinolinylmethoxy 4 5000 2282 2000
3ab 4-pyridinyloxy – 8 0.05 0.3
3b 4-quinolinylmethoxy 10 56 57 88
3c (2,6-dimethyl-4-pyridinyl)methoxy 6 1970 257 516
3d (3,5-dimethoxyphenyl)methoxy 1 2272 423 630
4a (2-methyl-4-quinolinyl)methoxy 2 5000 533 1106
4b (2-methyl-4-quinolinyl)methoxy 15 5000 3000 2000
4c (2-methyl-4-quinolinyl)methoxy 91 5000 3000 2000
5a methoxy 274 1060 8 104
5b benzyloxy 705 5000 3 4
5c 3,5-dimethylbenzyloxy 229 5000 136 2000
5d 3,5-dimethoxybenzyloxy 27 5000 491 2000
6a methoxy 200 76 16 28
6b (2-methyl-4-quinolinyl)methoxy 45 5000 491 2000
a Since semipurified pTACE was used in the routine assay, Ki values were not determined for most of the compounds.
b The MMP data for compounds 2a and 3a were taken from the literature; no values for pTACE were determined.
adjustment of the TACE conformation. This may in- Procedures. The inhibitor was initially placed in the site
“by hand” in an approximation to the presumed boundcrease the energy and necessitate an even more bulky
P1 than in the other series in order to compensate. orientation, with the hydroxamate positioned to chelate
the zinc ion in a bidentate fashion and with the intendedPerhaps the angle at which P1 is presented also differs
somewhat. Importantly, TACE selectivity was achieved P1 moiety extending into S1. After refinement by mo-
lecular dynamics (see Experimental Procedures), nowith 5d despite the conjectured difference in binding
mode. substantial changes in the modeled TACE were appar-
ent, and the ligand was oriented so that the oxygenAnother novel MMP inhibitor (6a) from our laboratory
incorporates 1-phenyl-1-cyclopropanecarboxamide. The atoms of the hydroxamic acid were about 2.0 A˚ distant
from the zinc, and the carbonyl oxygen of the lactamcyclopropane had been introduced by design in order
to increase the population of conformers required for formed hydrogen bonds with the amides of both L129
and G130 (Figure 5). We did not attempt docking tobinding to MMPs. Once again, introduction of a TACE-
selective P1 group, in this case a 2-methyl-4-quinolinyl- MMP-1 because of its foreshortened S1 pocket, and
crystal structures of MMP-2 and MMP-9 were not avail-methoxy group, not only improved activity for pTACE but
also considerably improved selectivity over MMP-1, -2, able. Because of the probabilistic nature of any homol-
ogy model, particularly one with as many large insertionsand -9. The results with scaffold families 1–6 suggest
not only the validity of the selectivity hypothesis, but as the TACE one, no further docking into TACE of com-
pounds was carried out.also the transferability of selectivity from one scaffold
to another by simple substitution of identical or very Docking of 1c and 1d was, however, attempted with
MMP-3 in the hope of elucidating reasons for selectivitysimilar P1 substituents.
against MMP-2 and -9, but we found that MMP-3 ac-
commodates these P1 chains adequately. The modelsComputer Docking of Inhibitors
We docked inhibitor 1c into the active site of the TACE suggest that 1c and 1d bind to MMP-3 with P1 in an
extended conformation, in contrast to the proposedmodel using the protocol outlined in the Experimental
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Figure 5. Superposition of the Inhibited
TACE Crystal Structure onto a Computer
Generated Complex of Molecule 3d with the
TACE Homology Model
The protein crystal structure is shown in cyan
and its associated inhibitor in green. The ho-
mology model is colored yellow, and mole-
cule 3d is colored white. Zinc atoms are or-
ange, and water molecules are magenta.
Portions of the two protein structures for
which the conformations overlay and the se-
quences correspond are depicted with cylin-
ders and ribbons; regions where either the
sequences or structures differ are repre-
sented as a thin cylindrical trace.
bent orientation in TACE (Figure 5). A subsequent assay It is also of interest to examine the inhibitors in the two
structures. The atoms of the hydroxamic acid moietieswith MMP-3 indicated that although 1d is selective for
TACE over MMP-3, activity is reduced by only about overlay well, and the methyne of the crystallographic
inhibitor’s P1 isobutyl group is located in the center30-fold (our unpublished data), indicating free energy
differences too small to be perceived with these meth- of the proximal ring of the modeled inhibitor’s P1. In
addition, its distal ring is positioned at the location ofods. In addition, it has been shown that flexibility and
mobility of both protein and ligand can play a role by three crystallographic water molecules. These observa-
tions indicate that the core of the homology model, se-increasing the entropy of the system [25]. Screening
against an extended set of enzymes will most likely be lectivity hypothesis, and computer-docked inhibitor
structure are all consistent with the crystallographicallynecessary to achieve a uniform selectivity profile.
Although we did not dock representative molecules determined TACE/inhibitor complex.
from the other series into the TACE homology model,
intuition suggests they bind similarly, as each contains
a hydroxamic acid to coordinate zinc, an oxygen likely Significance
to form a hydrogen bond with amides of the  strand
above the catalytic site, and a long and flexible P1 The central importance of TNF- as an anti-inflamma-
tory target has been well established by the therapeu-substituent to occupy S1.
tic success of both anti-TNF- antibody and TNFR
II receptor fusion proteins. The zinc metalloenzymeComparison with Crystal Structure
Recently, the crystal structure of TACE with a hydrox- TACE that processes this cytokine represents an at-
tractive small-molecule target for medicinal research.amic acid inhibitor became available (PDB file 1bkc) [26],
enabling evaluation of the accuracy of the homology Here we have described the steps leading to the devel-
opment of inhibitors effective in TACE and selectivemodel and computer docked structure. We were able
to superimpose the  carbon atoms of 117 of the 255 with respect to a representative set of MMPs, MMP-1,
-2, and -9.residues of the model onto those of the TACE crystal
structure with an rms deviation of 1.45 A˚. The superim- Comparative modeling of TACE based on the struc-
ture of the snake venom protein atrolysin resulted inposed regions included all five strands of the character-
istic  sheet, the MxP turn, and all three characteristic a plausible homology model. Careful inspection of the
model and comparison with the crystal structure ofhelices. A fourth helix, present in both TACE and reproly-
sin structures but not a feature of MMPs, was modeled inhibited MMP-3 suggested the S1 pocket as a selec-
tivity determinant for TACE. Examination of the periph-with the wrong sequence of residues. As expected, the
conformation of most loops differed considerably in the ery of this pocket highlighted a key residue differ-
ence—a tyrosine, conserved in all members of thetwo structures. The superimposed structures are shown
in Figure 5. MMP family, is replaced in TACE by the much smaller
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and represented implicitly by points of a grid. Force field parametersalanine, opening the side of the pocket and thus rein-
for the ligands were assembled from the AMBER atomic parameterforcing the selectivity hypothesis.
list, and charges were calculated using MOPAC [32] and the AM1By incorporation of appropriate P1 substituents into
Hamiltonian. Inhibitors were initially docked “by hand,” and the sys-
a -lactam-derived hydroxamic acid inhibitor, we were tems were then energy minimized and refined by short (20 ps) runs
able to achieve the desired selectivity. Transferability of molecular dynamics. During the simulations, distances between
zinc and N atoms of the chelating histidine residues, and betweenof the selectivity mechanism into five other series of
zinc and O atoms of the catalytic site Glu, were constrained to 2.1inhibitors was then demonstrated by simple substitu-
and 4.8 A˚, respectively (the values are close to those appearing intion at P1. Computer modeling was used to dock a
crystal structures of MMPs), with a force constant of 10.0 kcal/sample inhibitor into TACE in a convincing manner.
mol·A˚2. In molecular dynamics runs of the TACE model, atoms of
Comparison with a subsequently determined X-ray the main chain were constrained to their positions in the starting
crystal structure of inhibited TACE indicated our model structure using a very weak harmonic force constant of 0.5 kcal/
mol·A˚2. No constraints were imposed on the ligand, which was com-to be consistent with the known structural information.
pletely free to move. As in previous work with thermolysin [33],Thus, despite inaccuracies on the periphery of the
the hydroxamic acid was charged, and the catalysic site Glu washomology model, the fidelity of its protein core and
protonated. The final step was minimization of the average structuresubstrate binding site enabled identification of the
computed over the last 3 ps of simulation.
means of achieving specificity and, together with ef-
fective molecular design, the development of highly Inhibitor Synthesis and Testing
potent and selective compounds. Synthesis of inhibitors 1a–1g in enantiomerically pure form was
described in reference [1]. Experimental details for inhibitors 2b–2c
Experimental Procedures and 6a–6b were disclosed in previously published patent applica-
tions WO9958528 and WO0059874. Description of synthesis and
Sequence Analysis full experimental details of 5a–5d will be reported elsewhere [24].
Sequence alignments were carried out using the GCG suite of pro- Inhibitors 3b–3d were synthesized following the sequence described
grams (Wisconsin Package Version 8, Genetics Computer Group, below. Compounds 4a–4c were prepared using conditions analo-
Madison, WI): modules BestFit and Gap for pairwise and PileUp for gous to those for 3c.
multiple alignments. Sequences of the catalytic domains of MMP-1, Due to the fact that US patent 5,830,742 covers the usage of
-3, and -8 were extracted from Protein Data Bank files of their crystal truncated human TACE, we used semipurified TACE from porcine
structures (1hfc, 1sln, and 1mnc, respectively). The sequences of spleen as the primary assay. According to both the TACE homology
MMP-2 and MMP-9 were obtained from SWISS-PROT files model and the subsequently determined crystal structure, no non-
cog2_human and cog9_human and aligned with the other MMPs in conserved residues abut the proposed inhibitor binding site, sug-
order to determine the approximate beginning and end residues gesting pTACE as a suitable substitute for human enzyme. Counter-
of their catalytic domains. Similarly, the sequences of reprolysins screen assays included MMP-2 and -9 as representative members
adamalysin and atrolysin were taken from PDB files 1iag and 1htd, having deep S1 sites and MMP-1 as a representative with shallow
while those of jararhagin, trimerelysin, trigramin, and rhodostomin S1. Details of these assays are described in a previous
were obtained from SWISS-PROT (files disj_botja, hr1b_trifl, publication [34].
disa_triga, and disr_agkrh). The individual sequences were com-
pared with each other and with the sequence of TACE, obtained Synthesis of Hydroxamic Acids 3b–3d
from Ashok Amin at NYU. Alignments were generated for TACE with 4-Hydroxybenzenesulfonyl chloride (0.41 g, 0.22 mmol) in methylene
the set of reprolysins and with the set of MMPs, for the MMPs taken chloride (1 ml) was added dropwise to methyl (S )-2,2-dimethyl-3-
in pairs, for atrolysin versus adamalysin, and for TACE with atrolysin thiomorpholinecarboxylate (0.37 g, 0.20 mmol) in pyridine (4 ml) at
and with each of the individual MMPs. The alignment of atrolysin room temperature. After stirring for 30 min, the solvent was removed
with TACE was further modified during the homology-building stage and the residue taken up in ethyl acetate-water (1:1, 20 ml). The
(vide supra). mixture was extracted with ethyl acetate (3	), and the combined
extracts were washed with 10% citric acid (2	), water, and brine,
Homology Modeling dried over MgSO4, and concentrated. The residue was purified by
Many homology models of TACE were made in the course of this flash chromatography (silica gel, 50% ethyl acetate:hexane) to pro-
work. At the outset models were built using XLOOK (LOOK, version vide methyl (S)-4-[(4-hydroxyphenyl)sulfonyl]-2,2-dimethyl-3-thio-
3, Molecular Applications Group, Palo Alto, CA). Each model was morpholinecarboxylate (249 mg, 37%) as a light yellow solid: 1H
inspected for conformance to conventional principles of protein NMR (300 MHz, CDCl3) 
 7.60 (m, 2H), 6.88 (m, 2H), 5.71 (s, 1H), 4.41
architecture (for example charged and polar residues should be (s, 1H), 4.06 (dt, 1H, J  2.7, 11.7 Hz), 3.75 (dt, 1H, J  2.9, 12.8
located predominantly on exposed faces of  sheets, on polar sides Hz), 3.43 (s, 3H), 3.13 (m, 1H), 2.46 (dt, 1H, J  2.6, 12.9 Hz), 1.62
of amphiphilic helices, or in loops). Sequence alignments were then (s, 3H), 1.27 (s, 3H); MS (ESI) m/z 344 (MH).
adjusted and new models created. Cesium carbonate (396 mg, 1.22 mmol) was added in one portion
The alignment used in homology modeling was further optimized to the phenol obtained from the previous step (140 mg, 0.41 mmol),
in order to maximize sequence similarity in segments corresponding sodium iodide (79 mg, 0.53 mmol), and 4-chloromethyl-2,6-dimeth-
to secondary structural elements of the homolog’s crystal structure. ylpyridine hydrochloride (101 mg, 0.53 mmol) in anhydrous DMSO
At later stages of model-building, we attempted to optimize the (4 ml) at room temperature. The mixture was stirred for 2.5 hr and
conformation of short loops (fewer than 8 residues) using procedure then diluted with water and extracted with ethyl acetate (3	). The
FRAGLE (FRAGment Locate and Extract) [27], which presents to combined organic layers were washed with water (2	) and brine,
the user a choice of fragments from well-refined protein structures dried over MgSO4, and concentrated. The residue was purified by
whose end residues possess backbone conformations which match flash chromatography (silica gel, 50% to 80% ethyl acetate:hexane)
those of residues immediately preceding and following the loop to to provide methyl (S)-4-[[4-[(2,6-dimethyl-4-pyridinyl)methoxy]phe-
be inserted. nyl]sulfonyl]-2,2-dimethyl-3-thiomorpholinecarboxylate (157 mg,
82%) as a waxy white solid: 1H NMR (300 MHz, CDCl3) 
 7.65 (m,
2H), 6.98 (m, 2H), 5.07 (s, 2H), 4.41 (s, 1H), 4.05 (m, 1H), 3.74 (m,Molecular Modeling
Molecular surfaces were calculated with program GRASP [28], and 1H), 3.36 (s, 3H), 3.11 (m, 1H), 2.54 (s, 6H), 2.46 (m, 1H), 1.62 (s, 3H),
1.27 (s, 3H); MS (ESI) m/z 465 (MH).the program PSSHOW [29] was used for visualization of molecular
structure. Docking of inhibitors was carried out using Bforce [30], The ester obtained from the previous step was heated to reflux
in 6 N HCl (10 ml) for 15 hr. The solvent was removed in vacuo,a modified version of AMBER [31] that uses a mobile ligand and
active site, and a fixed “bulk” consisting of the rest of the protein and the residue was dried by evaporation with toluene (2	) and
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chloroform (2	). This provided (S)-4-[[4-[(2,6-dimethyl-4-pyridinyl) Gilbert, R., Gordon, J.L., et al. (1994). Processing of tumor necro-
sis factor-alpha precursor by metalloproteinases. Nature 370,methoxy]phenyl]sulfonyl]-2,2-dimethyl-3-thiomorpholinecarboxcy-
lic acid as a brittle foam that was taken to the next step without 555–557.
7. Black, R.A., Rauch, C.T., Kozlosky, C.J., Peschon, J.J., Slack,further purification: 1H NMR (300 MHz, CD3OD) 
 7.77 (s, 2H), 7.72
(d, 2H, J  8.8 Hz), 7.18 (d, 2H, J  8.8 Hz), 5.42 (s, 2H), 4.34 (s, J.L., Wolfson, M.F., Castner, B.J., Stocking, K.L., Reddy, P.,
Srinivasan, S., et al. (1997). A metalloproteinase disintegrin that1H), 3.97 (m, 1H), 3.73 (dt, 1H, J  2.6, 12.5 Hz), 3.04 (dt, 1H, J 
3.7, 13.2 Hz), 2.75 (s, 6H), 2.43 (m, 1H), 1.54 (s, 3H), 1.30 (s, 3H); MS releases tumor-necrosis factor-alpha from cells. Nature 385,
729–733.(ESI) m/z 451 (MH).
Diisopropyl ethyl amine (440 mg, 3.4 mmol) was added dropwise 8. Moss, M.L., Jin, S.L.C., Milla, M.E., Burkhart, W., Carter, H.L.,
Chen, W.-J., Clay, W.C., Didsbury, J.R., Hassler, D., Hoffman,to the acid from the previous step (0.34 mmol), BOP reagent (165 mg,
0.37 mmol), and hydroxylamine hydrochloride (71 mg, 1.02 mmol) in C.R., et al. (1997). Cloning of a disintegrin metalloproteinase
that processes precursor tumor-necrosis factor-alpha. NatureDMF (3 ml) at room temperature. The mixture was stirred overnight
and the solvent removed in vacuo. Purification by reverse-phase 385, 733–736.
9. Wojtowicz-Praga, S., Torri, J., Johnson, M., Steen, V., Marshall,HPLC (acetonitrile:water) provided (S)-4-[[4-[(2,6-dimethyl-4-pyridi-
J., Ness, E., Dickson, R., Sale, M., Rasmussen, H.S., Chiodo,nyl)methoxy]phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-3-thiomor-
T.A., et al. (1998). Phase I trial of marimastat, a novel matrixpholinecarboxamide 3c (65 mg, 33%) as a fluffy white powder after
metalloproteinase inhibitor, administered orally to patients withlyophilization: 1H NMR (300 MHz, DMSO) 
 7.71 (m, 4H), 7.15 (m,
advanced lung cancer. J. Clin. Oncol. 16, 2150–2156.2H), 5.40 (m, 2H), 4.07 (s, 1H), 3.88 (m, 1H), 3.34 (m, 1H), 3.07 (m,
10. Scatana, R. (2000). Prinomastat, a hydroxamate-based matrix1H), 2.72 (s, 6H), 2.43 (m, 1H), 1.54 (s, 3H), 1.20 (s, 3H); MS (ESI)
metalloproteinase inhibitor. A novel pharmacological approachm/z 466 (MH); HRMS calculated for (C21H27N3O5S2H) 466.1470,
for tissue remodelling-related diseases. Exp. Opin. Investig.found 466.1468.
Drugs 9, 2159–2165.(S)-N-hydroxy-2,2-dimethyl-4-[[4-(4-quinolinylmethoxy)phenyl]
11. Levitt, N.C., Eskens, F.A., O’Byrne, K.J., Propper, D.J., Denis,sulfonyl]-3-thiomorpholinecarboxamide (3b) was made using an
L.J., Owen, S.J., Choi, L., Foekens, J.A., Wilner, S., Wood, J.M.,analogous procedure to compound 3c, substituting 4-chlormeth-
et al. (2001). Phase I and pharmacological study of the oralylquinoline for 4-chloromethyl-4,6-dimethylpyridine. 1HNMR (300
matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in pa-MHz, DMSO) 
 8.96 (d, 1H, J  4.7 Hz), 8.21 (d, 1H, J  8.4 Hz),
tients with advanced solid cancer. Clin. Cancer Res. 7, 1912–8.08 (d, 1H, J  8.4 Hz), 7.85 (t, 1H, J  7.0 Hz), 7.73 (m, 2H), 7.63
1922.(d, 2H, J  8.8 Hz), 7.26 (d, 2H, J  8.8 Hz), 5.78 (s, 2H), 3.99 (s,
12. Nelson, F.C., and Zask, A. (1999). The therapeutic potential of1H), 3.88 (m, 1H), 3.69 (m, 1H), 2.81 (m, 1H), 2.43 (m, 1H), 1.35 (s,
small molecule TACE inhibitors. Exp. Opin. Investig. Drugs 8,3H), 1.11 (s, 3H); MS (ESI) m/z 488 (MH); HRMS calculated for
383–392.(C23H25N3O5S2  H) 488.1301, found 488.1300.
13. Nagase, H., Barrett, A.J., and Woessner, J.F., Jr. (1992). Nomen-(S)-4-[[4-[(3,5-Dimethoxyphenyl)methoxy]phenyl]sulfonyl]-
clature and glossary of the matrix metalloproteinases. MatrixN-hydroxy-2,2-dimethyl-3-thiomorpholinecarboxamide(3d) was
Suppl. 1, 421–424.made in an analogous procedure to compound 3c, substituting 3,5-
14. Schechter, I., and Berger, A. (1967). On the size of the activedimethoxybenzylchloride for 4-chloromethyl-4,6-dimethylpyridine:
site in proteases. I. Papain. Biochem. Biophys. Res. Commun.1H NMR (300 MHz, DMSO) 
 7.54 (d, 2H, 8.8 Hz), 7.10 (d, 2H, 8.8
27, 157–162.Hz), 6.58 (s, 2H), 6.43 (s, 1H), 5.08 (s, 2H), 3.99 (s, 1H), 3.91 (m, 1H),
15. Bode, W., and Maskos, K. (2001). Structural studies on MMPs3.71 (s, 6H), 3.32 (m, 1H), 2.81 (m, 1H), 2.42 (m, 1H), 1.36 (s, 3H),
and TIMPs. Methods Mol. Biol. 151, 45–77.1.13 (s, 3H); MS (ESI) m/z 519 (MNa); HRMS calculated for
16. Dhanaraj, V., Ye, Q.Z., Johnson, L.L., Hupe, D.J., Ortwine, D.F.,(C22H28N2O7S2  H) 497.1417, found 497.1422.
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